Abstract:Huntington Disease (HD) is a fatal genetic disease in which most striatal projection neurons (SPNs) degenerate. The central biological question about HD pathogenesis has been how the disease-causing DNA repeat expansion (CAGn) in the huntingtin (HTT) gene leads to neurodegeneration after decades of apparent latency. Inherited HTT alleles with a longer CAG repeat hasten disease onset; the length of this repeat also changes over time, generating somatic mosaicism, and genes that regulate DNA-repeat stability can influence HD age-at-onset. To understand the relationship between a cell's CAG-repeat length and its biological state, we developed a single-cell method for measuring CAG-repeat length together with genome-wide RNA expression. We found that the HTT CAG repeat expands from 40-45 CAGs to 100-500+ CAGs in HD-vulnerable SPNs but not in other striatal cell types, with these long DNA-repeat expansions acquired at different times by individual SPNs. Surprisingly, somatic expansion from 40 to 150 CAGs had no apparent effect upon gene expression - but neurons with 150-500+ CAGs shared profound gene-expression changes. These expression changes involved hundreds of genes, escalated alongside further CAG-repeat expansion, eroded positive and then negative features of neuronal identity, and culminated in expression of senescence/apoptosis genes. Rates of striatal neuron loss across HD stages reflected the rates at which neurons entered this biologically distorted state. Our results suggest that HTT CAG repeats in striatal neurons undergo decades of biologically quiet expansion, then, as they asynchronously cross a high threshold, cause SPNs to degenerate quickly and asynchronously. We conclude that, at any moment in the course of HD, most neurons have an innocuous (but unstable) huntingtin gene, and that HD pathogenesis is a DNA process for almost all of a neuron's life.

Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease

Identification of genetic modifiers of Huntington's disease somatic CAG repeat instability by in vivo CRISPR-Cas9 genome editing

Identification of genetic modifiers of Huntington′s disease somatic CAG repeat instability by in vivo CRISPR-Cas9 genome editing

Genetic modifiers of somatic expansion and clinical phenotypes in Huntington's disease reveal shared and tissue-specific effects

Huntington’s Disease: Relationship Between Phenotype and Genotype

Huntington’s Disease: Complex Pathogenesis and Therapeutic Strategies

Exploring molecular mechanisms, therapeutic strategies, and clinical manifestations of Huntington's disease

Complex Pathogenesis and Therapeutic Strategies

Long somatic DNA-repeat expansion drives neurodegeneration in Huntington disease

Advances in Gene and Cellular Therapeutic Approaches for Huntington’s Disease

Navigating triplet repeats sequencing: concepts, methodological challenges and perspective for Huntington's disease

Integrated analysis on transcriptome and behaviors defines HTT repeat-dependent network modules in Huntington's disease

Latest Advances on New Promising Molecular-Based Therapeutic Approaches for Huntington’s Disease

Polyglutamine Expansion in Huntingtin and Mechanism of DNA Damage Repair Defects in Huntington's Disease

Huntington's Disease: Molecular Basis of Pathology and Status of Current Therapeutic Approaches.

Progress in studies of gene therapy for Huntington's disease

A modifier of Huntington's disease onset at the MLH1 locus

Huntington Disease: Linking Pathogenesis to the Development of Experimental Therapeutics

Multiple pathways contribute to the pathogenesis of Huntington disease

Therapy development in Huntington disease: From current strategies to emerging opportunities

Huntington's Disease: Latest Frontiers in Therapeutics